Paradigm Capital Management Inc. NY Acquires 959,100 Shares of MiMedx Group, Inc $MDXG

Paradigm Capital Management Inc. NY raised its holdings in MiMedx Group, Inc (NASDAQ:MDXG) by 39.1% during the first quarter, Holdings Channel.com reports. The institutional investor owned 3,410,300 shares of the company’s stock after buying an additional 959,100 shares during the quarter. Paradigm Capital Management Inc. NY’s holdings in MiMedx Group were worth $13,471,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Nantahala Capital Management LLC purchased a new stake in MiMedx Group in the third quarter worth $10,237,000. Marshall Wace LLP raised its holdings in MiMedx Group by 864.9% in the 4th quarter. Marshall Wace LLP now owns 1,381,288 shares of the company’s stock worth $9,351,000 after purchasing an additional 1,238,132 shares in the last quarter. Hillsdale Investment Management Inc. purchased a new stake in shares of MiMedx Group in the 4th quarter worth about $7,134,000. Disciplined Growth Investors Inc. MN boosted its stake in shares of MiMedx Group by 283.0% during the 3rd quarter. Disciplined Growth Investors Inc. MN now owns 1,383,451 shares of the company’s stock valued at $9,656,000 after purchasing an additional 1,022,202 shares in the last quarter. Finally, OP Asset Management Ltd bought a new stake in shares of MiMedx Group during the 1st quarter valued at about $2,406,000. 79.15% of the stock is owned by hedge funds and other institutional investors.

MiMedx Group Price Performance

MDXG stock opened at $4.20 on Friday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.81 and a current ratio of 5.39. The firm has a 50 day moving average price of $3.86 and a 200-day moving average price of $4.31. MiMedx Group, Inc has a 52-week low of $3.03 and a 52-week high of $7.99. The firm has a market capitalization of $625.57 million, a price-to-earnings ratio of 21.00 and a beta of 1.45.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings results on Wednesday, April 29th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.02. The company had revenue of $58.99 million for the quarter, compared to the consensus estimate of $65.80 million. MiMedx Group had a return on equity of 21.03% and a net margin of 7.88%. Equities research analysts forecast that MiMedx Group, Inc will post -0.09 EPS for the current fiscal year.

Analysts Set New Price Targets

MDXG has been the subject of several research analyst reports. Weiss Ratings lowered shares of MiMedx Group from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, May 18th. Citizens Jmp lowered their target price on MiMedx Group from $7.00 to $6.00 and set a “market outperform” rating for the company in a research note on Thursday, April 30th. Craig Hallum dropped their price target on MiMedx Group from $10.00 to $7.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. Finally, Wall Street Zen downgraded MiMedx Group from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, MiMedx Group currently has a consensus rating of “Moderate Buy” and an average target price of $8.50.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.